Analyst Conference Summaries

Biotechnology Investor Aids

ImmunoGen
IMGN

conference date: November 2, 2018 @ 5:00 AM Pacific Time

ImmunoGen Price Run-Up Driven by Potential Trial Data [Feb. 6, 2018 at SA]

AML Therapies, Part 2: Agios and Immunogen [September 29, 2016 at Seeking Alpha]

ImmunoGen Oversold Despite Strong Pipeline [July 7, 2016 at Seeking Alpha]

2018
 
May 4, 2018
July 27, 2018
Nov. 2, 2018
 
2017
May 5, 2017
July 28, 2017
Nov. 3, 2017
Feb. 9, 2018
2016
04/29/2016
08/04/2016
10/28/2016
02/17/2017

Immunogen (IMGN) is a clinical-stage biotechnology company specializing in ADC's (antibody-drug conjugates) for cancer and other diseases.

Immunogen web site


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMD
 AMGN
 BIIB
 CLDX
 CELG
 EPZM
 GILD
 GLYC
 INO
 INTC
 ISRG
 JUNO
 MACK
 MCHP
 MYL.
 NVDA
 PLX
 REGN
 SGEN
 XLNX
 XLRN
 

Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2017 William P. Meyers